Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...
TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...
In this podcast, Philadelphia cornea and glaucoma surgeon Brian Shafer, MD, discusses the procedures and processes involved ...
Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy ...
The conversation explored DME subtypes, treatment selection, and the roles of VEGF, ANG2, and inflammatory cytokines—particularly in severe or poorly controlled patients who respond inadequately to ...
The EnVision Summit—billed as the “ultimate gathering place for ophthalmic and optometric professionals”—has come to a close ...
The authors of a new study 1 emphasized the clear visual benefits that low-vision patients experience during low-vision rehabilitation. However, they cited “substantial gaps” in the research in that ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
Ophthalmology Times, hosted by Douglas D. Koch, MD, Professor and Allen, Mosbacher, and Law Chair in Ophthalmology at the ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing durability as a primary unmet need in nAMD and DME management.
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results